# Safety, Efficacy and Pharmacokinetics of GreenGene™ F to Previously Treated Patients With Severe Hemophilia A

> **NCT01619046** · PHASE3 · UNKNOWN · sponsor: **Green Cross Corporation** · enrollment: 124 (estimated)

## Conditions studied

- Hemophilia A

## Interventions

- **BIOLOGICAL:** GreenGene™ F and an approved recombinant Factor VIII product
- **BIOLOGICAL:** GreenGene™ F
- **BIOLOGICAL:** GreenGene™ F
- **BIOLOGICAL:** GreenGene™ F

## Key facts

- **NCT ID:** NCT01619046
- **Lead sponsor:** Green Cross Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2013-03
- **Primary completion:** 2015-07
- **Final completion:** 2015-09
- **Target enrollment:** 124 (ESTIMATED)
- **Last updated:** 2014-07-03

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01619046

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01619046, "Safety, Efficacy and Pharmacokinetics of GreenGene™ F to Previously Treated Patients With Severe Hemophilia A". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01619046. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*